Semprus BioSciences Corp. tapped a pair of executives to lead its business and product development operations.
The Cambridge, Mass.-based firm is developing a "dual-functional" vascular access catheter using its Semprus Surfaces covalent chemical bonding technique, "a permanent, non-leaching biomaterial modification to the device surface" according to the company’s website.
Semprus said it named Donald Anderson as its vice president of business development and Laurence Roth as VP of product development.
Anderson, most recently co-founder and managing director of Boston-based consulting company Cavan Partners LLC (where he worked as a consultant to Semprus), and is a former VP of marketing and business development at Biosphere Medical Inc. (NSDQ:BSMD), according to a press release.
Roth was also a medical device industry consultant, with a background in operations, product and business development with Arsenal Medical Inc., Percardia and eventual Genzyme Biosurgery (NSDQ:GZBX) acquisition Focal Inc.